JP2020533283A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533283A5
JP2020533283A5 JP2020511956A JP2020511956A JP2020533283A5 JP 2020533283 A5 JP2020533283 A5 JP 2020533283A5 JP 2020511956 A JP2020511956 A JP 2020511956A JP 2020511956 A JP2020511956 A JP 2020511956A JP 2020533283 A5 JP2020533283 A5 JP 2020533283A5
Authority
JP
Japan
Prior art keywords
composition
composition according
endoxyphen
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511956A
Other languages
English (en)
Japanese (ja)
Other versions
JP7766316B2 (ja
JP2020533283A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050272 external-priority patent/WO2019051416A1/en
Publication of JP2020533283A publication Critical patent/JP2020533283A/ja
Publication of JP2020533283A5 publication Critical patent/JP2020533283A5/ja
Priority to JP2023116961A priority Critical patent/JP7901563B2/ja
Priority to JP2025011662A priority patent/JP2025061858A/ja
Application granted granted Critical
Publication of JP7766316B2 publication Critical patent/JP7766316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511956A 2017-09-11 2018-09-10 エンドキシフェンを製造および使用する方法 Active JP7766316B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023116961A JP7901563B2 (ja) 2017-09-11 2023-07-18 エンドキシフェンを製造および使用する方法
JP2025011662A JP2025061858A (ja) 2017-09-11 2025-01-27 エンドキシフェンを製造および使用する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762556884P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US62/556,799 2017-09-11
US62/556,884 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US62/624,787 2018-01-31
US201862693885P 2018-07-03 2018-07-03
US62/693,885 2018-07-03
PCT/US2018/050272 WO2019051416A1 (en) 2017-09-11 2018-09-10 METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116961A Division JP7901563B2 (ja) 2017-09-11 2023-07-18 エンドキシフェンを製造および使用する方法

Publications (3)

Publication Number Publication Date
JP2020533283A JP2020533283A (ja) 2020-11-19
JP2020533283A5 true JP2020533283A5 (enExample) 2021-10-21
JP7766316B2 JP7766316B2 (ja) 2025-11-10

Family

ID=65635248

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511956A Active JP7766316B2 (ja) 2017-09-11 2018-09-10 エンドキシフェンを製造および使用する方法
JP2023116961A Active JP7901563B2 (ja) 2017-09-11 2023-07-18 エンドキシフェンを製造および使用する方法
JP2025011662A Pending JP2025061858A (ja) 2017-09-11 2025-01-27 エンドキシフェンを製造および使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023116961A Active JP7901563B2 (ja) 2017-09-11 2023-07-18 エンドキシフェンを製造および使用する方法
JP2025011662A Pending JP2025061858A (ja) 2017-09-11 2025-01-27 エンドキシフェンを製造および使用する方法

Country Status (12)

Country Link
US (12) US11261151B2 (enExample)
EP (1) EP3681491A4 (enExample)
JP (3) JP7766316B2 (enExample)
KR (3) KR20260048646A (enExample)
CN (2) CN111328280A (enExample)
AU (3) AU2018329202B2 (enExample)
CA (1) CA3073836A1 (enExample)
IL (3) IL272924B2 (enExample)
MX (1) MX2020002649A (enExample)
SG (1) SG11202002105WA (enExample)
TW (2) TWI878810B (enExample)
WO (1) WO2019051416A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110564962B (zh) * 2019-10-14 2020-12-22 中南大学 一种黑白钨混合矿的冶炼方法
CN113975279A (zh) * 2021-10-13 2022-01-28 复旦大学附属肿瘤医院 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用
IL314075A (en) * 2022-01-12 2024-09-01 Atossa Therapeutics Inc Compositions of (Z)-endoxifen and methods for their enrichment
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use
AU2024294879A1 (en) * 2023-07-19 2026-01-22 Atossa Therapeutics, Inc. Endoxifen compositions and methods of use thereof and synthesis thereof
AU2024409147A1 (en) 2023-12-18 2026-06-25 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof
AU2025207748A1 (en) 2024-01-08 2026-07-02 Atossa Therapeutics, Inc. Endoxifen for treatment of rare cancers
WO2025207636A1 (en) 2024-03-25 2025-10-02 Atossa Therapeutics, Inc. Endoxifen for treating duchenne muscular dystrophy

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
DE3561012D1 (en) 1984-06-12 1987-12-23 Nat Res Dev Preparation of tamoxifen
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
WO2003039530A1 (en) 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
EP2050443B1 (en) 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1572178B1 (en) 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544851A (en) 2003-06-23 2008-03-28 Macrochem Corp A vanishing cream base composition suitable for topical administration of an active agent to an animal or plant
US7531578B2 (en) 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE548375T1 (de) 2004-01-16 2012-03-15 Cedarburg Pharmaceuticals Inc Exemestan und zwischenprodukte davon und verfahren zu dessen herstellung
US8436029B2 (en) 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2603857A1 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
KR100917698B1 (ko) 2005-07-06 2009-09-21 시코르, 인크. 레트로졸의 제조를 위한 개선된 방법
CA2617934A1 (en) 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
US8034824B2 (en) 2005-10-12 2011-10-11 Kowa Co., Ltd. Iontophoretic preparation for treatment of breast cancer and/or mastitis
WO2007067773A2 (en) 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8058302B2 (en) 2006-06-05 2011-11-15 Cadila Healthcare Limited Process for preparing pure anastrozole
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
WO2008066783A2 (en) 2006-11-27 2008-06-05 Ariad Pharmaceuticals, Inc. Therapeutic materials and methods
WO2008067991A2 (en) 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090068190A1 (en) 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2212301B1 (en) 2007-11-28 2012-02-29 Fresenius Kabi Oncology Limited An improved process for preparation of letrozole and its intermediates
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
WO2009129352A2 (en) 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
WO2010043404A1 (en) 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
US20100098659A1 (en) 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
ES2624557T3 (es) 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
CN101891635B (zh) * 2009-05-21 2014-06-04 扬子江药业集团有限公司 枸橼酸他莫昔芬的晶型及晶型a的制备方法
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011031561A2 (en) 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011072244A1 (en) 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
KR101308258B1 (ko) 2010-10-15 2013-09-13 씨제이제일제당 (주) 엔독시펜의 신규한 제조 방법
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9200045B2 (en) 2011-03-11 2015-12-01 President And Fellows Of Harvard College Small molecule-dependent inteins and uses thereof
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
FR2980972B1 (fr) 2011-10-05 2014-02-28 Commissariat Energie Atomique Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes.
WO2013134230A1 (en) 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150321983A1 (en) 2012-10-19 2015-11-12 Fermion Oy A process for the preparation of ospemifene
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
WO2014141292A2 (en) 2013-03-04 2014-09-18 Intas Pharmaceuticals Limited Endoxifen citrate polymorph and process for preparing the same
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
TW201536278A (zh) * 2013-05-31 2015-10-01 Del Mar Pharmaceuticals 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途
EP3057985A4 (en) 2013-10-18 2017-05-31 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3092027A4 (en) 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
CA2942301A1 (en) 2014-03-11 2015-09-17 Repros Therapeutics Inc. Clomiphene synthesis using a single solvent
EP3152579A4 (en) 2014-06-04 2018-01-17 Atossa Genetics Inc. Molecular mammography
CN104230723B (zh) 2014-08-21 2016-08-24 凯莱英医药集团(天津)股份有限公司 托瑞米芬的合成方法
EP3283061A4 (en) 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
WO2016187122A1 (en) 2015-05-15 2016-11-24 University Of Iowa Research Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
CA2992282A1 (en) 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
ES2883172T3 (es) * 2015-10-22 2021-12-07 Us Health Proceso para preparar (Z)-endoxifeno de alta pureza
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
CN111212635A (zh) 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
TW201919594A (zh) 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES

Similar Documents

Publication Publication Date Title
JP2005525369A5 (enExample)
JP2022546471A5 (enExample)
EP2769718B1 (en) Medicinal composition
JPWO2023027198A5 (enExample)
CN102395276A (zh) 硝唑尼特的控制释放药物剂型
JP2018504398A5 (enExample)
JP2022540421A5 (enExample)
JP2019516684A5 (enExample)
CN1970547B (zh) 非布司他的晶型及其制备方法
WO2011160541A1 (zh) 托伐普坦固体分散体及其制备方法
WO2019029319A1 (zh) 包含柠檬苦素类化合物和双胍类化合物的组合产品
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
JP2022535893A5 (enExample)
JP2019218379A5 (enExample)
TWI491395B (zh) 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
WO2013139266A1 (zh) 含芬特明和托吡酯的联合产品及其制备方法
CN121568688A (zh) 因多昔芬组合物及其使用方法及其合成
US20050203115A1 (en) Narcotic-NSAID ion pairs
CN102973515B (zh) 一种治疗高血压、心绞痛的缓释制剂
JP2022500485A5 (enExample)
CN104876903A (zh) 二氢杨梅素的结晶形态、其制备方法以及药物组合物
JP2026504208A (ja) ベンゾイソチアゾール化合物、その医薬組成物および用途
JP2011529859A (ja) プラスグレル重硫酸塩及びその薬物組成物並びにその応用
JP2022177119A5 (enExample)
JPH11510168A (ja) 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法